Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
Strand et al. Rheumatology (Oxford). 2016 Feb 29. doi:pii: kev442. [Epub ahead of print]
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Strand et al. Rheumatology (Oxford). 2016 Feb 29. doi:pii: kev442. [Epub ahead of print]
Ann Rheum Dis. 2015;0:1-7. doi:10.1136/annrheumdis-2015-207872 [Epub ahead of print]
Clinical Therapeutics. 2015:37(8). [Epub ahead of print]
Mod Rheumatol. 2014 Dec 11:1–25. [Epub ahead of print]
J Rheumatol 2014;41;837-852
International Journal of Clinical Rheumatology June 2013; 8(3):311–13
Best Practice & Research Clinical Rheumatology 2010; 24:513-26
The New England Journal of Medicine 2012; 367(6):508-19